Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study

Table 5 Risk factors for tumor recurrence and death after propensity score matching

Tumor recurrence				Death
	OR	95%CI	P value		OR	95%CI	P value
Univariate				Univariate
Group (cHCC-CC)	2.15	1.162-3.977	0.015	Group (cHCC-CC)	2.134	1.142-3.987	0.018
Sex (male)	2.467	0.597-10.199	0.212	Sex (male)	1.536	0.475-4.964	0.474
Recipient age	0.973	0.928-1.021	0.266	Recipient age	1.009	0.962-1.057	0.725
Locoregional therapy before LT	1.78	0.855-3.706	0.123	Locoregional therapy before LT	2.304	1.026-5.171	0.043
Number of locoregional therapies before LT > 3	2.185	1.207-3.957	0.01	Number of locoregional therapies before LT > 3	1.241	0.683-2.254	0.478
MELD	0.944	0.889-1.002	0.056	MELD	0.993	0.947-1.041	0.758
Type of LT (DDLT)	0.771	0.239-2.493	0.664	Type of LT (DDLT)	1.999	0.891-4.488	0.093
ABO-incompatibility	1.094	0.526-2.277	0.81	ABO-incompatibility	0.439	0.157-1.228	0.117
Tumor size > 3 cm	2.541	1.406-4.592	0.002	Tumor size > 3 cm	2.426	1.341-4.386	0.003
Tumor number > 3	1.81	0.957-3.422	0.068	Tumor number > 3	1.458	0.749-2.839	0.267
Milan criteria (beyond)	2.893	1.573-5.322	0.001	Milan criteria (beyond)	2.261	1.242-4.119	0.008
Tumor grade 3 or 4	1.247	0.599-2.596	0.554	Tumor grade 3 or 4	1.268	0.610-2.639	0.525
Microvascular invasion	1.936	1.068-3.510	0.03	Microvascular invasion	1.873	1.032-3.400	0.039
PVTT	1.389	0.497-3.885	0.531	PVTT	1.836	0.722-4.669	0.202
BDTT	0.595	0.082-4.322	0.608	BDTT	2.035	0.487-8.504	0.33
Intrahepatic metastasis	2.192	1.172-4.101	0.014	Intrahepatic metastasis	1.742	0.923-3.289	0.087
Multicentric occurrence	1.313	0.687-2.512	0.41	Multicentric occurrence	0.967	0.489-1.915	0.924
Encapsulation	1.447	0.701-2.986	0.317	Encapsulation	1.305	0.626-2.723	0.478
Tumor necrosis	2.245	1.229-4.101	0.009	Tumor necrosis	2.56	1.383-4.740	0.003
AFP > 20 ng/mL	1.053	0.569-1.946	0.87	AFP > 20 ng/mL	1.333	0.733-2.425	0.346
PIVKA-II > 40 mAU/mL	1.202	0.639-2.263	0.568	PIVKA-II > 40 mAU/mL	1.422	0.762-2.651	0.268
Multivariate				Multivariate
Group (cHCC-CC)	2.531	1.191-5.376	0.016	Group (cHCC-CC)	2.281	1.057-4.922	0.036
Microvascular invasion	3.232	1.486-7.029	0.003	Tumor size > 3 cm	1.343	1.123-1.605	0.001
Number of locoregional therapies before LT > 3	2.33	1.235-4.396	0.009	Tumor number > 3	1.032	1.004-1.061	0.026

OR: Odds ratio; CI: Confidence interval; cHCC-CC: Combined hepatocellular carcinoma-cholangiocarcinoma; LT: Liver transplantation; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; MELD: Model for end-stage liver disease; DDLT: Deceased donor liver transplantation; PVTT: Portal vein tumor thrombosis; BDTT: Bile duct tumor thrombosis; AFP: Alpha-fetoprotein; PIVKA-II: Prothrombin-induced by vitamin K absence-II.